Medicating mood with maintenance in mind: Bipolar depression pharmacotherapy

Bipolar Disorders

Volumn 11, Issue SUPPL. 2, 2009, Pages 55-76

  Malhi, Gin S ^a   Adams, Danielle ^a   Berk, Michael ^b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ORYGEN RESEARCH CENTRE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Anticonvulsants; Antipsychotics; Bipolar depression pharmacotherapy; Lithium; Treatment recommendations

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CELECOXIB; CLOZAPINE; FLUOXETINE; GLUCOCORTICOID ANTAGONIST; LAMOTRIGINE; LITHIUM SALT; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZONISAMIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ADJUVANT THERAPY; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANOREXIA; ANXIETY; APLASTIC ANEMIA; APPETITE; ARTHRALGIA; ASTHENIA; ATAXIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BLEEDING; BLOOD DYSCRASIA; BLOOD TOXICITY; BLURRED VISION; BODY TEMPERATURE DISORDER; BRAIN DISEASE; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DELAYED DIAGNOSIS; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSLIPIDEMIA; DYSTONIA; ECG ABNORMALITY; ELECTROCONVULSIVE THERAPY; EPIGASTRIC DISCOMFORT; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART PALPITATION; HEPATITIS; HUMAN; HYPERAMMONEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPOMANIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; INDIGESTION; INSOMNIA; IRRITABILITY; JAUNDICE; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; MAINTENANCE THERAPY; MANIA; MEMORY DISORDER; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; MUSCLE RIGIDITY; MYALGIA; MYOCARDITIS; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; OROFACIAL DYSKINESIA; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARESTHESIA; PATIENT SAFETY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSORIASIS; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QT PROLONGATION; RECURRENCE RISK; REVIEW; RHINITIS; RISK REDUCTION; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN BRUISING; SKIN MANIFESTATION; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDE; SWEATING; TACHYCARDIA; TARDIVE DYSKINESIA; TASTE DISORDER; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VAGINA BLEEDING; VAGUS NERVE STIMULATION; VERTIGO; VOMITING; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

AFFECT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COGNITIVE THERAPY; COST OF ILLNESS; DATABASES, BIBLIOGRAPHIC; GUIDELINES AS TOPIC; HORMONE ANTAGONISTS; HUMANS;

EID: 66649085756     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00711.x     Document Type: Review

References (212)

1. Cade JF, Malhi GS. Cade's Lithium. Acta Neuropsychiatr 2007; 19: 125-126.
2. Aydemir O, Malhi GS. Aretaeus of Cappadocia. Acta Neuropsychiatr 2007; 19: 62-63.
3. Murray C, Lopez A. The Global Burden of Disease and Injury Series: Volume I: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press, 1996.
4. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th edn. text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
5. Malhi GS, Mitchell PB, Salim S. Bipolar Depression: Management options. CNS Drugs 2003; 17: 9-25.
6. Berk M, Berk L, Moss K, Dodd S, Malhi GS. Diagnosing bipolar disorder: how can we do it better? Med J Aust 2006; 184: 459-462.
7. Berk M, Dodd S, Callaly P et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord 2007; 103: 181-186.
8. Cahill C, Green M, Jairam R, Malhi G. Bipolar disorder in children and adolescents: Obstacles to early diagnosis. Early Interv Psychiatry 2007; 1: 138-149.
9. Hauser M, Pfennig A, Ozgurdal S, Heinz A, Bauer M, Juckel G. Early recognition of bipolar disorder. Eur Psychiatry 2007; 22: 92-98.
10. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002; 25: 685-698.
11. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
12. Mitchell PB, Wilhelm K, Parker G, Austin MP, Rutgers P, Malhi GS. The clinical features of bipolar depression: A comparison with matched major depressive disorder patients. J Clin Psychiatry 2001; 62: 212-216.
13. Malhi GS, Berk M. How to treat bipolar disorder. http://www.australiandoctor.com.au (accessed 14 April 2009).
14. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: A probabilistic approach. Bipolar Disord 2008; 10: 144-152.
15. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9: 114-125.
16. Martínez-Arán A, Vieta E, Torrent C et al. Functional outcome in bipolar disorder: The role of clinical and cognitive factors. Bipolar Disord 2007; 9: 103-113.
17. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: A meta-analysis. Acta Psychiatr Scand Suppl 2007; 434: 17-26.
18. Martínez-Arán A, Vieta E, Reinares M et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004; 161: 262-270.
19. Olley A, Malhi GS, Mitchell PB, Batchelor J, Lagopoulos J, Austin MP. When euthymia is just not good enough: The neuropsychology of bipolar disorder. J Nerv Ment Dis 2005; 193: 323-330.
20. Pavuluri MN, Schenkel LS, Aryal S et al. Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients. Am J Psychiatry 2006; 163: 286-293.
21. Dickstein DP, Treland JE, Snow J et al. Neuropsychological performance in pediatric bipolar disorder. Biol Psychiatry 2004; 55: 32-39.
22. Blumberg HP, Leung HC, Skudlarski P et al. A functional magnetic resonance imaging study of bipolar disorder: State- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry 2003; 60: 601-609.
23. Strakowski SM. Bipolar disorder and advances in neuroimaging: A progressive match. CNS Spectr 2006; 11: 267-268.
24. Malhi GS, Lagopoulos J. Making sense of neuroimaging in psychiatry. Acta Psychiatr Scand 2008; 117: 100-117.
25. Blumberg HP, Fredericks C, Wang F et al. Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord 2005; 7: 570-576.
26. Blumberg HP, Martin A, Kaufman J et al. Frontostriatal abnormalities in adolescents with bipolar disorder: Preliminary observations from functional MRI. Am J Psychiatry 2003; 160: 1345-1347.
27. Mitchell PB, Malhi GS. Bipolar depression: Phenomenological overview and clinical characteristics. Bipolar Disord 2004; 6: 530-539.
28. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
29. Kessler R, Tubinow D, Homes C, Abelson J, Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997; 27: 1079-1089.
30. Dilsaver SC, Chen YW, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski KJ. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997; 73: 47-56.
31. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: Risk and prevention. CNS Drugs 2003; 17: 491-511.
32. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (Suppl. 4): 1-50.
33. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
34. Royal Australian and New Zealand College of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004; 38: 280-305.
35. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149-173.
36. Malhi GS, Adams D, Lampe L et al. Clinical Practice Recommendations for Bipolar Disorder. Acta Psychiatr Scand 2009; 119: 27-46.
37. National Health and Medical Research Council. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. Canberra: Commonwealth of Australia, 1998.
38. Kupfer D. Long-term treatment of depression. J Clin Psychiatry 1991; 52: 28-34.
39. Goodwin GM, Anderson I, Arango C et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008; 18: 535-549.
40. Goldberg JF, Calabrese JR, Savibe BR et al. Mood destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J Clin Psychiatry 2009; in press.
41. Fieve RR, Platman SR, Plutchik RR. The use of lithium in affective disorders. II. Prophylaxis of depression in chronic recurrent affective disorder. Am J Psychiatry 1968; 125: 492-498.
42. Goodwin FK, Murphy DL, Bunney WE Jr. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Arch Gen Psychiatry 1969; 21: 486-496.
43. Greenspan K, Schildkraut JJ, Gordon EK, Baer L, Aronoff MS, Durell J. Catecholamine metabolism in affective disorders. 3. MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J Psychiatr Res 1970; 7: 171-183.
44. Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 1: 1319-1325.
45. Goodwin FK, Murphy DL, Dunner DL, Bunney WE Jr. Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972; 129: 44-47.
46. Noyes R Jr, Dempsey GM. Lithium treatment of depression. Dis Nerv Syst 1974; 35: 573-576.
47. Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976; 133: 373-378.
48. Baron M, Gershon ES, Rudy V, Jonas WZ, Buchsbaum M. Lithium carbonate response in depression. Prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Arch Gen Psychiatry 1975; 32: 1107-1111.
49. Donnelly EF, Goodwin FK, Waldman IN, Murphy DL. Prediction of antidepressant responses to lithium. Am J Psychiatry 1978; 135: 552-556.
50. Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: A meta-analysis. Br J Psychiatry 1991; 158: 666-675.
51. Kupfer DJ, Pickar D, Himmelhoch JM, Detre TP. Are there two types of unipolar depression? Arch Gen Psychiatry 1975; 32: 866-871.
52. Mendels J, Secunda SK, Dyson WL. A controlled study of the antidepressant effects of lithium carbonate. Arch Gen Psychiatry 1972; 26: 154-157.
53. Watanabe S, Ishino H, Otsuki S. Double-blind comparison of lithium carbonate and imipramine in treatment of depression. Arch Gen Psychiatry 1975; 32: 659-668.
54. Worrall EP, Moody JP, Peet M et al. Controlled studies of the acute antidepressant effects of lithium. Br J Psychiatry 1979; 135: 255-262.
55. Khan MC. Lithium carbonate in the treatment of acute depressive illness. Biol Psychiatry 1981; 161: 244-248.
56. Arieli A, Lepkifker E. The antidepressant effect of lithium. Curr Develop Psychopharmacol 1981; 6: 165-190.
57. Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: A clinical trial. Int Clin Psychopharmacol 1987; 2: 47-54.
58. Grof P. Chapter 14: Responders to long-term lithium treatment. In: Bauer M, Grof P, Müller-Oerlinghausen B eds. Lithium in Neuropsychiatry: The Comprehensive Guide. Abingdon, Oxon, England: Informa, 2006: 157-178.
59. Gershon S, Chengappa KNR, Malhi GS. Lithium specificity in bipolar illness: A classic agent for the classic disorder. Bipolar Disord 2009; 11 (Suppl. 2): 34-44.
60. Young AH, Carlsson A, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Lithium in adults with bipolar depression (Embolden I). Eur Psychiatry 2008; 23: S239.
61. Heit F, Nemeroff CB. Lithium augmentation of antidepressants in treatment-refractory depression. J Clin Psychiatry 1998; 59: 28-33.
62. Linder J, Fryo B, Petterson U, Werner S. Acute antidepressant effect of lithium associated with fluctuation of calcium and magnesium in plasma. Acta Psychiatr Scand 1989; 80: 27-36.
63. Bauer M, Ahrens B. Bipolar disorder. A practical guide to drug treatment. CNS Drugs 1996; 6: 35-52.
64. Carney SM, Goodwin GM. Lithium -a continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand 2005; 111: 7-12.
65. Bhagwagar Z, Goodwin GM. The role of lithium in the treatment of bipolar depression. Clin Neurosci Res 2002; 2: 222-227.
66. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; 3: CD003013.
67. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222.
68. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412.
69. Grof P, Hux M, Grof E, Arato M. Prediction of response to stabilizing lithium treatment. Pharmacopsychiatria 1983; 16: 195-200.
70. Davis JM. Chapter 10: Lithium maintenance of unipolar depression. In: Bauer M, Grof P, Müller-Oerlinghausen B eds. Lithium in Neuropsychiatry: The Comprehensive Guide. Abingdon, Oxon, England: Informa, 2006: 99-108.
71. van Gerven HA, Boer WH. Chronic renal function disorders during lithium use. Ned Tijdschr Geneeskd 2006; 150: 1715-1718.
72. El-Mallakh RS. Lithium: Actions and Mechanisms. Washington DC: American Psychiatric Press, 1996.
73. Ghaemi SN, Gilmer WS, Goldberg JF et al. Divalproex in the treatment of acute bipolar depression: A preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1840-1844.
74. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: A placebo-controlled study. J Affect Disord 2005; 85: 259-266.
75. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67: 207-212.
76. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: An update. J Affect Disord 2008; 109: 21-34.
77. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489.
78. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; 3: CD003196.
79. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374-1382.
80. Tohen MF, Ketter T, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
81. Calabrese J, Shelton M, Rapport D. A 20-month, double-blind, maintenance trial of lithium vs. divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152-2161.
82. Calabrese J, Bowden C, Sachs G, Ascher JA, Monaghan E, Rudd DG. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
83. Frye MA, Ketter T, Kimbrell T et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
84. Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-333.
85. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9.
86. van der Loos ML, Mulder PG, Hartong EG et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223-231.
87. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
88. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
89. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441.
90. Licht RW. Lamotrigine versus lithium in prophylaxis of bipolar disorder: a randomised study mimicking clinical practice. Bipolar Disord 2008; 10 (Suppl. 1): 27.
91. Goldsmith D, Wagstaff A, Ibbotson T, Perry C. Lamotrigine: A review of its used in bipolar disorder. Drugs 2003; 63: 2029-2050.
92. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders -a randomised study. J Affect Disord 1997; 43: 151-161.
93. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA, LitCar G. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144-151.
94. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14: 283-285.
95. Nasrallah HA, Ketter TA, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: A review of the literature. J Affect Disord 2006; 95: 69-78.
96. Tohen M, Vieta E, Calabrese J. Efficacy of olanzapine and olanzapine/ fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
97. Zhang W, Perry KW, Wong DT et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23: 250-262.
98. Brown EB, McElroy SL, Keck PE Jr et al. A 7-week comparison of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025-1033.
99. Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
100. Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-609.
101. McElroy S, Young AH, Carlsson A et al. A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Paroxetine in adults with bipolar depression (Embolden II). Eur Psychiatry 2008; 23: S239.
102. Weisler RH, Calabrese JR, Thase ME et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: A post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69: 769-782.
103. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009; 11: 225-255.
104. Hirschfeld RMA. Guideline watch (November 2005): Practice guideline for the treatment of patients with bipolar disorder, 2nd Edition. Focus 2007; 5: 34-39.
105. Vieta E, Gasto C, Colom F et al. Role of risperidone in bipolar II: An open 6-month study. J Affect Disord 2001; 67: 213-219.
106. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65: 1715-1719.
107. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008; 117: 253-259.
108. Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-216.
109. Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28: 13-20.
110. Metrick MS, Anand A. Open-label pilot study of adjunctive aripiprazole treatment for difficult to treat bipolar depression. Bipolar Disord 2008;10 (Suppl. 1): 38.
111. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
112. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-Month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290.
113. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345.
114. Brecher M, Anderssen H, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term phase III studies. Eur Psychiatry 2008; 23: S225-S226.
115. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment in bipolar I disorder with Quetiapine in combination with Lithium/ Divalproex: A placebo-controlled, randomized trial (North American trial D1447C00127). Eur Psychiatry 2008; 23: S237.
116. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
117. Nolen WA, Weisler RH, Neijber A, Hellqvist A, Paulsson B. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Presented at the 17th European Congress of Psychiatry, Lisbon, Portugal, 24-25 January, 2009.
118. Vieta E, Goikolea JM, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818-825.
119. Yatham LN, Binder C, Riccardelli R et al. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003; 18: 227-235.
120. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: A 2-year study of 10 patients. Int Clin Psychopharmacol 2008; 23: 88-94.
121. Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637.
122. Keck PE Jr, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491.
123. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14: 152-164.
124. Gao KMDP, Kemp DEMD, Ganocy SJP, Gajwani PMD, Xia GMDP, Calabrese JRMD. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. J Clin Psychopharmacol 2008; 28: 203-209.
125. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537-1547.
126. Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711-1722.
127. Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 2008; 10: 957-968.
128. Cassidy F. Antidepressant treatment practice in the face of STAR*D and STEP-BD. Bipolar Disord 2008; 10: 973-974.
129. Goldberg JF. The modern pharmacopoeia: A return to depressive realism? Bipolar Disord 2008; 10: 969-972.
130. Malhi GS. Upping the ante on antidepressants. Bipolar Disord 2008; 10: 975-978.
131. Nemeroff CB, Evans DL, Guyulai L et al. Double-blind, placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912.
132. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001; 62: 565-569.
133. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36.
134. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25.
135. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198.
136. Steckler T, Holsboer F, Reul JM. Glucocorticoids and depression. Best Pract Res Clin Endocrinol Metab 1999; 13: 597-614.
137. Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 2008; 1: CD005168.
138. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; 29: 1538-1545.
139. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23: 87-94.
140. Berk M, Copolov DL, Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder -a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475.
141. Frye MA, Grunze H, Suppes T et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164: 1242-1249.
142. Zarate CA Jr, Payne JL, Singh J et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.
143. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-566.
144. Ghaemi SN, Zablotsky B, Filkowski MM et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006; 26: 385-388.
145. Stoll AL, Severus WE, Freeman MP et al. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56: 407-412.
146. Keck PE Jr, Mintz J, McElroy SL et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60: 1020-1022.
147. Frangou SMDP, Lewis MBR, McCrone PP. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
148. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913-919.
149. Morriss RK, Faizal MA, Jones AP, Williamson PR, Bolton C, McCarthy JP. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; 1: CD004854.
150. Miklowitz DJ, Otto MW, Frank E et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 2007; 164: 1340-1347.
151. Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: A 1-Year randomized trial from the systematic treatment enhancement program. Arch Gen Psychiatry 2007; 64: 419-426.
152. Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007; 10: 123-129.
153. Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60: 904-912.
154. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: Randomised controlled trial. Br J Psychiatry 2006; 188: 313-320.
155. Lam DH, Watkins ER, Haywood P et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60: 145-152.
156. Lam DH, Bright J, Jones S et al. Cognitive therapy for bipolar illness: a pilot study of relapse prevention. Cognit Ther Res 2000; 24: 503-520.
157. Scott J, Garland A, Moorhead S. A pilot study of cognitive therapy in bipolar disorders. Psychol Med 2001; 31: 459-467.
158. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 2008; 192: 5-11.
159. Miklowitz DJ, Simoneau TL, George EL et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 48: 582-592.
160. Rea MM, Tompson MC, Miklowitz DJ, Goldstein MJ, Hwang S, Mintz J. Family-focused treatment versus individual treatment for bipolar disorder: Results of a randomized clinical trial. J Consult Clin Psychology 2003; 71: 482-492.
161. Frank E, Kupfer DJ, Thase ME et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62: 996-1004.
162. Colom F, Vieta E, Martínez-Arán A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407.
163. Lam DH, Hayward P, Watkins ER, Wright K, Sham P. Relapse prevention in patients with bipolar disorder: Cognitive therapy outcome after 2years. Am J Psychiatry 2005; 162: 324-329.
164. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000; 48: 593-604.
165. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-620.
166. Pantelis C, Malhi GS. Pillow talk: Catatnoic. Acta Neuropsychiatr 2008; 20: 44-45.
167. Philbrick KL, Rummans TA. Malignant catatonia. J Neuropsychiatry Clin Neurosci 1994; 6: 1-13.
168. Grunhaus L, Schreiber S, Dolberg OT, Hirshman S, Dannon PN. Response to ECT in major depression: Are there differences between unipolar and bipolar depression? Bipolar Disord 2002; 4 (Suppl. 1): 91-93.
169. Daly JJ, Prudic J, Devanand D et al. ECT in bipolar and unipolar depression: Differences in speed of response. Bipolar Disord 2001; 3: 95-104.
170. Zornberg GLM, Pope HGJM. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13: 397-408.
171. Silverstone P, Silverstone T. A review of acute treatments for bipolar depression. Int Clin Psychopharmacol 2004; 19: 113-124.
172. Kopecek M, Cerna L, Sulak J, Raszka M, Bares M, Seifertova D. Depressed patients perception of the efficacy of electroconvulsive therapy and venlafaxine therapy. Neuro Endocrinol Lett 2007; 28: 889-894.
173. Hallam K, Smith D, Berk M. Differences between subjective and objective assessments of the utility of Electroconvulsive therapy in patients with bipolar and unipolar depression. J Affect Disord 2009; 112: 212-218.
174. Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT 2003; 19: 10-16.
175. Rau A, Grossheinrich N, Palm U, Pogarell O, Padberg F. Transcranial and deep brain stimulation approaches as treatment for depression. Clin EEG Neurosci 2007; 38: 105-115.
176. Malhi G, Sachdev P. Novel physical treatments for the management of neuropsychiatric disorders. J Psychosomatic Res 2002; 53: 709-719.
177. Malhi G, Loo C, Cahill C, Lagopoulos J, Mitchell P, Sachdev P. "Getting physical": The management of neuropsychiatric
178. Dolberg OT, Dannon PN, Schreiber S, Grunhaus L. Transcranial magnetic stimulation in patients with bipolar depression: A double blind, controlled study. Bipolar Disord 2002; 4 (Suppl. 1): 94-95.
179. Li X, Nahas Z, Anderson B, Kozel FA, George MS. Can left prefrontal rTMS be used as a maintenance treatment for bipolar depression? Depress Anxiety 2004; 20: 98-100.
180. Xia G, Gajwani P, Muzina DJ et al. Treatment-emergent mania in unipolar and bipolar depression: Focus on repetitive transcranial magnetic stimulation. Int J Neuropsychopharmacol 2008; 11: 119-130.
181. Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008; 64: 455-460.
182. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: Risks and management. CNS Spectr 2006; 11: 465-471.
183. Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 2007; 20: 17-22.
184. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord 2006; 8: 625-639.
185. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
186. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-1088.
187. Schou M. Pharmacology and toxicology of lithium. Annu Rev Pharmacol Toxicol 1976; 16: 231-243.
188. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine. J Affect Disord 2007; 103: 5-11.
189. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal beIavior: Part 3: impact of antipsychotics. J Affect Disord 2007; 103: 23-28.
190. Yerevanian BI, Koek RJ, Mintz J, Akiskal HS. Bipolar pharmacotherapy and suicidal behavior: Part 2. the impact of antidepressants. J Affect Disord 2007; 103: 13-21.
191. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-550.
192. Sachs GS, Lafer B, Stoll AL et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-393.
193. Vieta E, Martínez-Arán A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63: 508-512.
194. Post RM, Altshuler LL, Leverich GS et al. Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189: 124-131.
195. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.
196. Kasper S, Calabrese JR, Johnson G et al. International Consensus Group on the evidence based pharmacological treatment of Bipolar I and Bipolar II Depression. J Clin Psychiatry 2008; 69: 1632-1646.
197. Calabrese JR, Kasper S, Johnson G et al. International Consensus Group on bipolar I depression treatment guidelines. J Clin Psychiatry 2004; 65: 569-579.
198. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003; 5: 85-97.
199. Malhi GS. Et tu bipolar II? Acta Neuropsychiatr 2007; 19: 267-268.
200. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108-111.
201. Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 37-42.
202. Rouget BW, Aubry J-M. Efficacy of psychoeducational approaches on bipolar disorders: A review of the literature. J Affect Disord 2007; 98: 11-27.
203. Reinares M, Colom F, Sanchez-Moreno J et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: A randomized controlled trial. Bipolar Disord 2008; 10: 511-519.
204. Frank E, Gonzalez JM, Fagiolini A. The importance of routine for preventing recurrence in bipolar disorder. Am J Psychiatry 2006; 163: 981-985.
205. Ng F, Dodd S, Berk M. The effects of physical activity in the acute treatment of bipolar disorder: A pilot study. J Affect Disord 2007; 101: 259-262.
206. Berk M, Ng F, Wang WV et al. Going up in smoke: Tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord 2008; 110: 126-134.
207. Berk M. Should we be targeting smoking as a routine intervention? Acta Neuropsychiatr 2007; 19: 131-132.
208. Krüger S, Young TL, Bräunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord 2005; 7: 205-215.
209. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: A framework for rational treatment selection. Hum Psychopharmacol 2004; 19: 369-386.
210. MIMS Online (database on the Internet). MIMS Australia. 2009 -(cited 28 January 20H9): Available from: http://mims.hcn.net.au.ezproxy2.library.usyd.edu.au/ifmx-nsapi/ mims-data/?MIval=2MIMS_ssearch 2009.
211. Australian Medicines Handbook (electronic book) July 2008. (cited 28 January 20H9): Available from: http://proxy7.use.hcn.com.au/.
212. National Institute for Health and Clinical Excellence. Bipolar Disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care: Clinical Guideline 38. London: NHS, 2006.